Molecular docking and ADMET studies of halogenated metabolites from marine sponges as inhibitors of wild-type and mutants PBP2 in Neisseria gonorrhoeae

• Published in: Journal of biomolecular structure & dynamics pp. 1 - 13
• Main Authors: Alanzi, Abdullah R, Alajmi, Mohammed F, Alqahtani, Moneerah J
• Format: Journal Article
• Language: English
• Published: England 13-12-2023
• Subjects: Gonorrhoea; Neisseria gonorrhoeae; molecular docking; ADMET; penicillin-binding protein 2
• ISSN: 0739-1102; 1538-0254
• DOI: 10.1080/07391102.2023.2292291

Gonorrhoea is a sexually transmitted infection (STI) caused by the bacteria
. Gonorrhoea symptoms can vary, although roughly 50% of women and 10% of men infected with
may be asymptomatic. If left untreated, gonorrhoea can cause major health problems. However, no effective treatment or vaccination is currently available. The enzyme penicillin-binding protein 2 (PBP2) is necessary for cell wall synthesis during
cell growth. The goal of this study is to investigate the molecular interactions of three PBP2 variants with halogenated marine sponge metabolites using molecular docking, molecular dynamic simulation, and ADMET analysis. The docking findings were evaluated using the glide gscore, and the top 20 compounds docked against each PBP2 protein receptor were chosen. Furthermore, the selected compounds underwent ADMET analysis, indicating that they have the potential for therapeutic development. Among the selected compounds, Bromoageliferin had the highest affinity for PBP2, Psammaplysin E for the penicillin-resistant variation of PBP2 protein, and Preaxinellamine for the cephalosporin-resistant variant of PBP2 protein. Additionally, MM-GBSA binding free energy and molecular dynamics simulations were used to support the docking investigations. The results of the study suggest that these compounds may eventually be used to treat gonorrhoea. However, computer validations were included in this study, and more in-vitro research is required to turn these prospective inhibitors into clinical drugs.Communicated by Ramaswamy H. Sarma.